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ABSTRACT 
Background: Thyroid nodules are usually diagnosed using fine-needle aspiration (FNA). 
The sensitivity limitations of FNA result in 10-30% of nodules being classified as 
“indeterminate”. The BRAFV600E mutation is associated with papillary thyroid carcinoma 
(PTC). We conducted a systemic review and meta-analysis to evaluate the diagnostic utility 
of the BRAFV600E mutation in indeterminate nodules.  
Method: PUBMED and EMBASE were searched for studies testing for the BRAFV600E 
involving indeterminate nodules (Thy3a, Thy3f, Thy4) and containing information on final 
surgical histopathology. Thirty two studies involving 3,150 indeterminate nodules were 
included in the analysis.  
Results: The overall sensitivity and specificity for BRAFV600E for the diagnosis of thyroid 
malignancy was 0.40 (95% CI:0.32–0.48) and 1.00 (95% CI:0.98–1.00) respectively. The 
diagnostic odds ratio (DOR) was 205.4 (95% CI:40.1-1052). With a Fagan plot, the post-test 
probability of thyroid cancer, given a negative mutation was 6%, but this rose to 92% with a 
positive result. On subgroup analysis, for Thy3a nodules, the pooled sensitivity and 
specificity for thyroid malignancy was 0.21 (95% CI:0.13-0.34) and 1.00 (95% CI:0.98-1.00). 
For Thy3f nodules, the pooled sensitivity and specificity was 0.09 (95% CI:0.03-0.20) and 
1.00 (95% CI:0.05-1.00) respectively. For Thy4 nodules, the corresponding sensitivity and 
specificity was 0.58 (95%CI:0.5-0.64) and 0.99 (95%CI:0.95-1.00) respectively.  
Conclusions: Despite a high specificity for thyroid cancer, BRAFV600E mutation has a low 
overall sensitivity and therefore has a limited diagnostic value as a single screening test.  
  
INTRODUCTION 
 
Thyroid cancer is the most common endocrine malignancy with increasing incidence 
worldwide.1 Recent data indicate that thyroid cancer is currently the fifth commonest cancer 
in the world, representing about 6% of all cancer incidence in women.2,3 Ultrasound-guided 
fine needle aspiration (US-FNA) is a crucial diagnostic tool for the identification of nodules 
harbouring malignancy.4 FNA is accurate, safe, cost-effective, and a minimally invasive 
procedure in the diagnosis of thyroid nodules.5 However, despite its high sensitivity, 
specificity and accuracy, FNA is limited by inadequate/insufficient samples (10-20%) or 
indeterminate cytological results (10-30%).4,6  Within the indeterminate category (Thy3a, 
Thy3f and Thy4), the risk of malignancy varies from between 5% and 75% depending on the 
different cytological classification.7 Within the category “atypia of undetermined 
significance” (AUS) or “follicular lesion of undetermined significance” (FLUS), the 
recommended management is clinical correlation and a repeat FNA at an appropriate time 
interval.8 However, following repeated FNA, 50% of patients will require diagnostic thyroid 
surgery, as the diagnosis is indeterminate.9,10 Within the “suspicious for follicular neoplasm” 
(SFN), “follicular neoplasm” (FN) and “suspicious for malignancy” (SFM) categories, 
thyroid surgery (thyroid lobectomy or total thyroidectomy) is usually recommended.4 
With the current clinical algorithm, especially in cases treated non-operatively, a false 
negative FNA result can lead to a delay in treatment and a less favourable prognosis.11,12 
Furthermore, a significant proportion of patients with indeterminate cytology will undergo 
diagnostic surgery and of these, only 10-40% turned out to be malignant on final 
histopathology resulting in unnecessary surgeries with the attendant risks and expenses.13 
Because of the inherent limitation of FNA, many efforts have been directed at improving its 
diagnostic accuracy especially in the diagnosis of thyroid malignancy.    
Since its initial description and association with thyroid cancer,14,15 the oncogenic BRAFV600E 
has been extensively studied and its potential in clinical application to diagnose thyroid 
cancer is increasingly recognized. It is the most common genetic mutation in thyroid cancers, 
occurring in 35% - 65% of cases of PTC.14 There is mounting evidence demonstrating that 
the BRAFV600E mutation may be associated with a poorer prognosis and more aggressive 
tumour behaviour (extrathyroidal extension, lymph node metastasis and recurrence).16 
Furthermore, BRAFV600E mutation was shown to be an independent prognostic factor for PTC 
recurrence and associated with increased cancer-related mortality.17,18  
 The aim of this study was to evaluate the sensitivity and specificity of the BRAFV600E 
mutation in predicting thyroid malignancy in indeterminate nodules. We undertook a 
systematic review and meta-analysis of the published literature describing the utility of 
BRAFV600E mutation in diagnosing indeterminate nodules. This updated meta-analysis also 
compares the diagnostic utility of BRAFV600E in different cytology within the indeterminate 
group. 
 
METHODS 
Search Strategy 
 
Studies evaluating the utility of BRAFV600E mutation in diagnosing thyroid malignancy in 
indeterminate nodules were reviewed. We searched PUBMED and EMBASE for English 
language publications relevant to our topic. Articles were identified using the following 
search terms: “BRAF”, “B-RAF”, “thyroid”, “indeterminate”, “undetermined”, “nodule”, 
“cytologically”, “cytology”, “FNA”, “FNAB”, “AUS”, “FLUS”, “FN/SFN” and “SFM”. We 
utilised the Boolean operator of “OR”, “AND” and “NOT” between the search terms (Table 
S1 in the Supplement). We also conducted a manual search for additional relevant studies in 
the reference lists of articles retrieved. The guidelines for Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) were used.19 
Inclusion and exclusion criteria 
The following inclusion criteria were used: (1) Pre-operative FNAs identifying indeterminate 
nodules (2) BRAFV600E mutation tested in these thyroid nodules; (3) The corresponding 
histopathology following surgical excision was reported; and (4) the sensitivity and 
specificity of BRAFV600E was reported or could be calculated from the data provided. For 
papers not acquired or those where data could not be extracted, respective authors were 
contacted. Reasons for study exclusions are detailed in Figure 1. We defined indeterminate 
nodules as those with no definitive diagnosis of benign, malignant; thus including AUS/ 
FLUS, FN/SFN, and SFM. This corresponds with Thy3a, Thy3f and Thy4 (Bethesda III-
V).20,21  
Data extraction and quality assessment 
Three reviewers (MJ, OO, and LH) independently extracted relevant data from each eligible 
study. The following data were collected: author’s name, year of publication, country, 
reference standard, method of BRAFV600E detection, number of participants and nodules 
involved, and number of samples with corresponding histopathological results. 
Disagreements and discordant values were resolved by discussion and joint review by all 
reviewers. Each eligible study was assessed for quality using the revised Quality Assessment 
for Studies of Diagnostic Accuracy (QUADAS-2) tools.22  
Data Synthesis and Statistical Analysis 
The main outcome parameters were; pooled sensitivity; specificity and positive likelihood 
ratio (PLR); and the corresponding confidence intervals (CIs) by random effect model. 
Pooled sensitivity and specificity for BRAFV600E test performance is displayed using a forest 
plot. Subgroup analyses were additionally performed according to different Thy 
classifications and BRAFV600E detection methods. Study heterogeneity was assessed using the 
Q-test and inconsistency index (I2 statistic). Test performance in the presence of 
heterogeneity was summarized using hierarchical summary receiver operator curves 
(HSROC) and area under the curve (AUC) was applied to demonstrate the overall diagnostic 
performance. To explore the sources of between-study heterogeneity, a meta-regression 
method of Reitsma et al.34 was applied to evaluate the effects of covariates. Diagnostic odds 
ratio (DOR) was also calculated as a single indicator measure of the diagnostic tests 
accuracy. Deek’s Funnel Plot Asymmetry Test was applied to visually determine the 
presence of publication bias.  
RESULTS 
Literature Search Outcome 
A total of 522 articles were retrieved; 190 articles were removed as duplicates and the 
remaining 332 studies screened. Upon initial abstract review, 181 articles were excluded (see 
Figure 1). The commonest exclusion reason was an inappropriate study focus (n=80). One 
hundred and nineteen articles were excluded upon secondary review. The remaining 32 
studies were selected for inclusion because they fulfilled the study criteria.  There was 100% 
agreement between reviewers at the level of study selection from full-text articles (Cohen 
weighted κ was 1.0; SD=0). Thirty two studies with a total of 3,150 indeterminate thyroid 
nodules were included in the meta-analysis.23–54 The main characteristics of the included 
studies are summarised in Table S2 in supplementary content. Overall, we observed high 
study quality across all the included studies (Figure S2 in supplementary).  
 
 
Overall Diagnostic performance 
The pooled sensitivity and specificity of BRAFV600E mutation in the diagnosis of thyroid 
malignancy was 0.40 (95% CI: 0.32-0.48) and 1.00 (95% CI, 0.98-1.00) respectively (Figure 
2, Table 1). Overall, BRAFV600E mutation has good diagnostic performance with AUC of 
0.87 (Figure 3). The pre-test probability of thyroid malignancy in indeterminate nodules was 
10% in this meta-analysis and the post-test probability of thyroid malignancy, given a 
negative mutation detection result, was 6%, but rose to 92% with a positive result (Figure 4). 
Significant heterogeneity was observed (P < 0.0001, I2 = 89.94% and P < 0.0001, 
I2 = 90.01%). The Deek’s funnel plot revealed an asymmetry test with P <0.0001 for the slope 
coefficient, demonstrating a publication bias. 
Thy3a 
For Thy3a category, the pooled sensitivity and specificity of BRAFV600E mutation in the 
diagnosis of thyroid malignancy was 0.21 (95% CI: 0.13 - 0.34) and 1.00 (95% CI: 0.98 - 
1.00) respectively, with significant heterogeneity (P < 0.0001, I2 = 91.96% and P < 0.0001, 
I2 = 89.51%) (Table 1). The AUC was 0.85. The DOR was 163 (95% CI: 11.2 – 2368). A 
Fagan plot revealed that with a pre-test probability of thyroid malignancy in indeterminate 
nodules of 10%, the post-test probability of thyroid malignancy, given a negative mutation 
detection result, was 8%, but 89% with a positive result. 
Thy3f 
For Thy3f, the pooled sensitivity and specificity of BRAFV600E mutation in the diagnosis of 
thyroid malignancy was 0.09 (95% confidence interval: 0.03 - 0.20) and 1.00 (95% CI: 0.05 - 
1.00) respectively (See Table 1). The AUC was 0.77. A Fagan plot revealed that the post-test 
probability of thyroid malignancy, given a negative mutation detection result was 9% and 
100% with a positive result. 
Thy4 
For Thy4, the pooled sensitivity and specificity was 0.58 (95% CI: 0.5 - 0.64) and 0.99 (95% 
CI: 0.95 - 1.00) respectively (See Table 1). The AUC was 0.87. The Fagan plot, 
demonstrated that the post-test probability of thyroid malignancy, given a negative mutation 
detection result, was 5%, and 90% with a positive result.  
Subgroup analysis according to BRAFV600E detection methods 
A subgroup analysis was performed to determine whether there was any fundamental difference in 
sensitivity and specificity based on the methods by which BRAFV600E is detected. Overall, there was a 
significant difference in the ability of each method to detect BRAFV600E mutation. Both Sanger 
sequencing (n=15) and real time PCR (n=10) achieved 100% specificity with false negative rates of 
26.8% and 23.6% respectively. Pyrosequencing method (n=4) resulted in 97% specificity with 
comparable false negative rates of 24.4%. Immunohistochemistry method (n=3) resulted in a much 
lower specificity of 91% and a much higher false negative rate of 38.9% in this cohort (See Table 1).    
Histopathology 
Among the 3,150 indeterminate thyroid nodules, 670 were positive for the BRAFV600E 
mutation (21.3%). Of the 1,487 thyroid cancer, 662 (44.5%) tested positive for BRAFV600E 
mutation. The various histologic subtypes are summarized in the supplementary content. PTC 
and its histologic subtypes were the most common malignancy representing 99.8% of all 
malignancy in this group (n = 661). The most common histological subtype was classical 
PTC (n= 638), followed by follicular variant PTC (n = 21) and tall cell PTC (n = 2). Only 1 
nodule with the BRAFV600E mutation was reported as a Hürthle cell carcinoma, a variant of 
follicular neoplasm.  Eight nodules with a BRAFV600E mutation were histologically benign 
(false positive). The prevalence of BRAFV600E mutation varies according to different 
cytological groups and populations studied. The prevalence rate of BRAFV600E mutation in 
indeterminate nodules was 21.3%. For Thy3a, Thy3f and Thy4, the prevalence rate was 
12.8%, 3.6% and 49.7% respectively.  
DISCUSSION 
 
Incidental findings of thyroid nodules are becoming more common. Being able to accurately 
distinguish between those that require surgery and those that do not is a significant challenge, 
with an indeterminate result occurring in approximately 10%-30% of thyroid FNAs.6 Some 
patients, following consultation with their surgeons opt for an operative approach. 
Nonetheless, 60% of indeterminate nodules are benign on final pathological analysis; 
resulting in unnecessary surgery in a majority of patients.8 AUS/FLUS on a single FNAC is 
associated with a finding of malignancy on final pathology in between 15% and 30% of 
patients. In those with two FNAC results showing AUS/FLUS the risk of malignancy rises to 
25%.7 
The association of BRAFV600E mutation with PTC was initially suggested by Cohen et al in 
2003.14 The application of BRAFV600E mutation as a preoperative diagnosis tool for PTC was 
suggested by Xing et al in 2004.55 Since then, it has been extensively studied and available 
data favours its clinical use as an adjunct to FNA in the preoperative diagnosis of thyroid 
malignancy. Despite its high specificity, BRAFV600E mutation alone is unlikely to provide a 
full picture of thyroid carcinogenesis. Other genetic mutations that have been implicated in 
thyroid carcinoma include RET-PTC, PAX8-PPARγ rearrangements and RAS point 
mutations.37 In fact, several panels testing for these common genes including BRAFV600E 
mutation are undergoing evaluation for clinical application. The Quest Diagnostics Thyroid 
Cancer Mutation Panel which incorporates the above genes demonstrates a PPV of 88%, 87% 
and 95% respectively for AUS/FLUS, FN and SFM.33 In our study we found that BRAFV600E 
mutation alone demonstrated a PPV of 96.9%, 95.4% and 99.8% respectively for the same 
categories. Although this seems counter-intuitive, the most likely explanation for this is 
probably because the study by Nikiforov et al included a relatively smaller number of 
patients in a population where the prevalence of BRAFV600E mutation is possibly low. 
However, it is worth mentioning that a thyroid nodule tested positive for any of these genes 
(BRAFV600E, RET-PTC or PAX8-PPARγ) was associated with 100% risk of cancer.34  
Furthermore, because BRAFV600E mutation occurs only in 35-65% of cases of PTC, and has 
not been found in follicular carcinoma,55 its clinical application as a sole marker in 
preoperative thyroid cancer diagnosis remains limited. In our study, we found that only 
44.5% of thyroid cancer tested positive for BRAFV600E mutation. Therefore, a question 
remains on the indeterminate thyroid nodules tested negative for BRAFV600E mutation in 
which malignancy cannot be ruled out. In this case, several alternatives are feasible such as 
the utility of molecular profiling tests. Veracyte’s gene-expression classifier (GEC) for 
example incorporates 167 genes to classify thyroid nodules as either benign or suspicious and 
has a sensitivity and specificity of 92% and 52% respectively.56 In addition, Keutgen et al 
demonstrated that a panel of 4-micro RNAs (MiR-222, miR-328, miR-197 and miR-21) in a 
preliminary setting correctly identified benign and malignant indeterminate nodules with 
100% sensitivity and 86% specificity.57 These panels of molecular tests provide an excellent 
assessment for indeterminate thyroid nodules with increasing use in clinical setting. Despite 
this, their use widespread use may be limited by the cost incurred in each sample tested. The 
commercial cost of the Quest Diagnostics Thyroid Cancer Mutation Panel for example is 
about $3000 per sample while that of Veracyte’s GEC is about $3,200 per sample.58 In 
comparison, BRAFV600E testing is already quite established in clinical setting and costs 
approximately $500 - $600 between different institutions. Therefore, it could be argued that 
BRAFV600E mutation testing offers a more cost-effective approach as a first molecular test for 
patients with indeterminate nodules especially in areas where sophisticated molecular testing 
is not available.   
The limitations observed in this meta-analysis are those common to many meta-analyses: 
namely publication bias; selection bias; lack of complete datasets from individual studies and 
between-study heterogeneity. Publication bias was observed in our meta-analysis. In our 
search strategy, we attempted to include as many key words and relevant works as possible, 
although we acknowledge that this review may not be exhaustive. We searched only 
PUBMED and EMBASE as we believed that these two databases represent the majority of 
candidate papers, although this may have resulted in “missing papers”. Despite these 
concerns, we believe that the papers included in our review account for the vast majority of 
all the papers relevant to the topic and were otherwise representative.    
Heterogeneity between studies was also observed, and may represent a further potential 
source of bias. Study heterogeneity is pervasive in meta-analyses, and in this meta-analysis it 
is contributed to mainly by variations in study design, patient selection and demography, 
clinical setting, BRAFV600E detection methods, the type of reference standards, or a 
combination of these factors. Design flaws within the studies enrolled may also contributed to 
the heterogeneity. We controlled for between-study heterogeneity using the random-effects 
regression model, taking into account a number of clinically important covariates. 
Nevertheless, we appreciate that residual confounders may still be present.  
 
CONCLUSION 
 
While the authors accept that some of the limitations of the study include false negative and 
false positive rates, used in the correct clinical setting BRAFV600E testing could aid 
stratification of indeterminate nodules into a more high risk category, and therefore one that 
warrants surgical excision. In areas where molecular profiling tests are not routinely 
performed, BRAFV600E mutation could be tested as an adjunct to FNAs in indeterminate 
thyroid nodules. Our analysis supports a decision that all patients with a BRAFV600E-positive 
FNA should be offered the choice of total thyroidectomy because of the high risk of 
malignancy (98.8% in the cohort reviewed herein) and its association with poor prognosis. 
Despite this, the value of BRAFV600E mutation as a single screening test for patients with 
indeterminate nodules is limited due to its low sensitivity. Future direction of research may 
include assessment on its clinical integration in thyroid nodule assessment in general.  
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Figure 1. Literature Search of Eligible studies 
a The same study could be excluded for multiple reasons  
b Focused on techniques and methods on performing FNAC 
  
522 Records identified through 
database search  
 194 PUBMED 
 328 EMBASE 
 
 
332 Records screened 
151 Full-text articles assessed for 
eligibility 
32 Studies included in quantitative 
meta-analysis 
190 Duplicate records excluded 
181 Records excludeda 
 60 Methodological FNA studyb 
 16 Imaging as predictor 
 17 Focused on prognosis or survival 
 88 Others 
119 Records excluded 
 19 Entire population had cancer diagnosis 
 16 Not involving indeterminate nodules 
 18 No FNAC 
 15 No BRAFV600E Analysis 
 8 Nodules <10 in number 
 8 No corresponding surgical histopathology 
 35 Other 
  
 
Figure 2. Forest plot for the sensitivity and specificity of BRAFV600E mutation in diagnosing 
thyroid malignancy in indeterminate nodules 
The pooled sensitivity was 0.40 (95% CI: 0.32-0.48) and the pooled specificity was 1.00 
(95% CI: 0.98-1.00). 
  
Figure 3. HSROC curve 
The HSROC curve shows the 95% confidence and prediction regions around mean operating 
sensitivity and specificity point after outlier is excluded. Area under the curve (AUC) is 0.87. 
  
 
 
 
 
Figure 4. Fagan’s nomogram to evaluate the clinical utility of BRAFV600E mutation 
The Fagan plot showed a pre-test probability of 10% to develop a thyroid malignancy in 
indeterminate nodules. The post-test probability of thyroid malignancy given a negative 
BRAFV600E mutation was 6%; and 92% with a positive result. 
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Table 1. Pooled results of the meta-analysis of the diagnostic accuracy of BRAF V600E mutation detection in thyroid malignancy 
DOR= diagnostic odds ratio.  
  
Variables Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
Likelihood ratio DOR (95% CI) 
All indeterminate nodules 0.40 (0.32-0.48) 1.00 (0.98-1.00) 98.7  164.0  
Thy3a nodules 0.21 (0.13-0.34) 1.00 (0.98-1.00) 76.7  97.1  
Thy3f nodules 0.09 (0.03-0.20) 1.00 (0.98-1.00) 23539  25068  
Thy4 nodules 0.58 (0.50-0.64) 0.99 (0.95-1.00)  79.2  185.1  
BRAF detection methods     
 PCR Sanger sequencing (n=15) 0.45 (0.42-0.49) 1.00 (0.99-1.00) 172.2 314.7 
Real time PCR (n=10) 0.32 (0.28-0.37) 1.00 (0.99-1.00) 249.7 366.6 
Pyrosequencing (n=4) 0.60 (0.52-0.68) 0.97 (0.92-0.99) 20.6 50.26 
Immunohistochemistry (n=3) 0.56 (0.48-0.63) 0.91 (0.72-0.99) 6.4 13.36 
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SUPPLEMENTARY FIGURES AND TABLES 
 
Table S1. Literature search algorithm 
Table S2. Participants and study characteristics  
Figure S1. Summary of study quality according to QUADAS-2 
Figure S2. Deek’s funnel plot with superimposed regression line to determine publication 
bias. 
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No Search terms PUBMED EMBASE Search 
results 
#1 BRAF OR B-RAF  7343 15,042 22,385 
#2 thyroid 174,765 214,948 389,713 
#3 Nodule OR undetermined OR 
indeterminate 
374,033 84,434 458,467 
#4 cytologically OR cytology OR FNA OR 
FNAB OR AUS OR FLUS OR FN/SFN 
OR SFM 
226,456 167,998 394,454 
#5 #1 AND #2 AND #3 AND English[la] 239 407 646 
#6 #4 AND case reports[pt] 0 48 48 
#7 #4 AND letter[pt] 4 3 7 
#8 #4 AND review[pt] 24 74 98 
#9 #4 AND editorial[pt] 1 11 12 
#10 #4 AND practice guideline[pt] 0 8 8 
#11 #4 AND historical article[pt] 0 0 0 
#12 #4 AND news[pt] 1 0 1 
#13 #4 AND meta-analysis[pt] 1 6 7 
#14 #6 OR #7 OR #8 OR #9 OR #10 OR #11 
OR #12 OR #13 
30 94 124 
#15 #5 NOT #14 149 309 522 
 
Table S1. Literature search algorithm 
Key. [la] language, [pt] publication type 
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Study Country Study 
Method 
BRAF detection method FNA 
Reporting 
Total 
nodules 
TP FP FN TN BRAF 
incidence 
Agretti et al 35 Italy Prospective PCR Sanger Sequencing NCI 54 1 0 13 40 1.8% 
Capelli et al 36 Italy Prospective PCR Pyrosequencing BTA 56 10 0 20 26 17.9% 
Liu et al 37 China Prospective PCR Pyrosequencing BSRTC 63 6 0 8 49 9.5% 
Poller et al 38 UK Prospective Real-time PCR BTA 19 5 0 5 9 26.3% 
Johnson et al 39 UK Prospective Real-time PCR BTA 68 5 0 21 42 7.4% 
Brahma et al 40 Indonesia Prospective PCR Sanger Sequencing NR 19 5 0 11 3 26.3% 
Kloos et al 41 USA Prospective Real-time PCR BSRTC 208 20 1 55 132 10.1% 
Kleiman et al 42 USA Retrospective PCR Sanger sequencing BSRTC 310 13 0 76 221 4.2% 
Rossi et al 43 Italy Prospective PCR Sanger sequencing NCI 123 14 0 29 80 11.4% 
Cañadas-Garre et al 44 Spain Prospective PCR Sanger sequencing BSRTC 45 5 0 11 31 10.6% 
Nikiforov et al 45 USA Prospective Real-time PCR BSRTC 513 17 0 104 392 3.3% 
Moses et al 46 USA Prospective PCR Sanger Sequencing NCI 137 13 0 30 94 9.5% 
Cantara et al 47 Italy Prospective PCR Sanger Sequencing NR 95 23 0 30 42 24.2% 
Marchetti et al 48 Italy Retrospective PCR Sanger Sequencing BTA 52 18 0 15 19 34.6% 
Nikiforov et al 49 USA Prospective PCR Sanger Sequencing NCI 103 14 0 27 62 13.6% 
Sapio et al 50 Italy Prospective Real-time PCR NCI 67 10 0 16 41 14.9% 
Pizzolanti et al 51 Italy Prospective Real-time PCR NR 19 2 0 2 15 10.5% 
Sapio et al 52 Italy Prospective Real-time PCR NCI 36 4 0 4 28 11.1% 
Cohen et al 53 USA Retrospective PCR Sanger Sequencing NR 55 5 0 27 23 9.1% 
Ohori et al 54 USA Retrospective Real-time PCR BSRTC 117 3 0 17 97 2.6% 
Zatelli et al 55 Italy Prospective PCR Sanger Sequencing NCI 107 11 0 20 76 10.3% 
Park et al 56 Korea Retrospective PCR Pyrosequencing BSRTC 73 30 2 28 13 42.5% 
Hyeon et al 57 Korea Retrospective PCR Sanger Sequencing BSRTC 147 87 1 37 22 59.9% 
Seo et al 58 Korea Retrospective Real-time PCR BSRTC 48 10 0 21 17 26.3% 
Koh et al 59 Korea Retrospective Immunohistochemistry BSRTC 91 32 1 49 9 36.3% 
Lee et al 60 Korea Prospective PCR Sanger sequencing NCI 126 79 0 27 20 62.7% 
Kang et al 61 Korea Retrospective Real-time PCR BSRTC 102 57 0 38 7 55.9% 
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Kim et al 62 Korea Prospective PCR Pyrosequencing NCI 74 52 1 9 12 71.6% 
Kim et al 63 Korea Prospective Immunohistochemistry NR 80 50 1 24 5 63.8% 
Chung et al 64 Korea Retrospective PCR Sanger Sequencing NR 25 3 1 5 16 16.0% 
Moon et al 65 Korea Retrospective PCR Sanger Sequencing NR 91 42 0 42 7 46.2% 
Kwak et al 66 Korea Retrospective Immunohistochemistry NCI 27 16 0 4 7 59.3% 
    TOTAL 3150 662 8 825 1657  
 
 
Table S2. Participants and study characteristics 
NR = Not reported; NCI = National Cancer Institute; BTA = British Thyroid Association; BSRTC = Bethesda system for reporting thyroid 
cytology
6 
 
 
 
 
Figure S1. Summary of study quality according to QUADAS-2 
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Figure S2. Deek’s funnel plot with superimposed regression line to determine publication 
bias.
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